Mr. Stephen Lockyer reports

MEDX ANNOUNCES THE APPOINTMENT OF JEFFREY MORRIS AS VP OF SALES AND MARKETING

MedX Health Corp. has appointed veteran health-care-industry leader Jeffrey Morris as vice-president of sales and marketing.

With over 20 years of experience, Mr. Morris has worked for some of the most recognized global health-care and pharmaceutical brands such as Pfizer Inc., Boehringer-Ingelheim Canada, Merck Canada Inc., Novartis Vaccines and Sanofi Pasteur. Mr. Morris brings a strong record of establishing new territory clinic and physician relationships, implementing and leading large-scale sales and marketing teams, and driving sales results.

"I am honoured to be joining MedX Health at this pivotal stage of growth for the company," said Mr. Morris. "With our unique teledermatology technology platform, I look forward to establishing MedX as an industry leader."

"We are very pleased to have Jeffrey join our team," said Stephen Lockyer, chief executive officer of MedX Health. "We searched for a recognized health-care executive in the diagnostics space, a leader with proven sales and marketing expertise, one who is results-driven, and up to the task of building a strong team at MedX. Jeffrey met all of those criteria, and we are glad to have him aboard. He will be a critical part of our success."

About MedX Health Corp.

MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy on DermSecure telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products, SIAmetrics, SIMsys and MoleMate, which MedX manufactures in its ISO 13485-certified facility. SIAmetrics, SIMsys and MoleMate include hand-held devices that use patented technology utilizing light and its remittance to view up to two millimetres beneath suspicious moles and lesions in a pain-free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration, and Conformite Europeenne for use in Canada, the United States, Australia, New Zealand, the European Union, Brazil and Turkey.